Arena Pharmaceuticals, Inc.
Obesity drug developer records loss of $0.46 per share
Published in Pharma Investments, Ventures and Law Weekly, November 20th, 2005
Total revenues in the third quarter of 2005 were $7.4 million, compared to $4.4 million in the third quarter of 2004. Total revenues in the 9 months ended September 30, 2005, were $17.4 million, compared to $11.6 million in the 9 months ended September 30, 2004.
Arena reported a net loss allocable to common stockholders in the third quarter and the 9 months ended September 30, 2005 of $16.1 million, or $0.46 per share, and $57.5 million, or $1.69 per share, respectively. This compares with a net loss allocable to common...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
More Articles from Pharma Investments, Ventures and Law Weekly
- Alpharma, Inc.
U.S., global generics business sold to Actavis for $810M - Anika Therapeutics, Inc.
Hyaluronic acid-based therapy developer reports 57% increase in revenues - AtheroGenics, Inc.
Chronic inflammatory disease drug maker posts loss of $0.61 per share - Bio-Bridge Science
Vaccine maker listed on OTCBB - BioSyntech, Inc.
Agreement signed with Korean pharmaceutical company for purchase of 1.5M shares of stock - Bioniche Life Sciences, Inc.
Bladder cancer drug developer signs agreement for private financing - More from this issue of Pharma Investments, Ventures and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
